Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been diagnosed with refractory CSU and who remain symptomatic despitestandard-dose H1 antihistamine treatment.
Epistemonikos ID: f645b230efce0fb82fcbea5ad08b8b3f14e4eb3b
First added on: May 15, 2024